NASDAQ$AUPH
Aurinia Pharmaceuticals Inc. · Q1 2021 earnings
Q1 2021 earnings · · Investor relations
Briefing
Reported first quarter 2021 financial results with FDA approval, launch, and early market penetration of LUPKYNIS.
Aurinia Pharmaceuticals reported a net loss of $50.4 million for the quarter ended March 31, 2021. Revenues were $0.9 million, primarily from commercial sales of LUPKYNIS, which began in January 2021. Cash and cash equivalents and investments totaled $360.9 million as of March 31, 2021.
- FDA approved, launched, and achieved early market penetration of LUPKYNIS as the first approved oral therapy for lupus nephritis (LN).
- Received over 250 patient start forms by the end of the first quarter.
- Cash and cash equivalents, and investments totaled $360.9 million at March 31, 2021.
- LUPKYNIS trajectory is on track against internal projections.
Headline financials
Revenue & EPS history
Aurinia · Revenue · Quarterly
$914K
Revenue by segment
Aurinia · $914K total across 2 segments · Q1 2021
- Net product sales$884K—96.7%
- License, collaboration and royalty revenue$30K—3.3%
Forward guidance
Aurinia anticipates several milestones, including filing a marketing authorization application (MAA) with the European Medicines Agency (EMA) during the first half of 2021, initiating a study of voclosporin in adolescent patients (VOCAL study) during the second half of 2021, and reporting top-line results from the ongoing AURORA-2 continuation study during the first quarter of 2022.
Tailwinds
- Filing a marketing authorization application (MAA) with the European Medicines Agency (EMA) during the first half of 2021 with partner, Otsuka.
- Abstracts discussing voclosporin accepted for presentation at the Annual European Congress of Rheumatology (EULAR 2021 Congress), June 2 – 5, 2021, and at the Nephrology Virtual Congress (ERA-EDTA 2021), June 5 – 8, 2021.
- Initiating a study of voclosporin in adolescent patients (VOCAL study) during the second half of 2021.
- Reporting top-line results from the ongoing AURORA-2 continuation study during the first quarter of 2022.
- Market access will continue to improve as the rate of COVID vaccinations in the United States continues to climb and healthcare centers re-open their doors to patients
Headwinds
- Difficulties Aurinia may experience in completing the commercialization of voclosporin.
- The market for the LN business may not be as estimated.
- Aurinia may have to pay unanticipated expenses.
- Aurinia may not be able to obtain sufficient supply to meet commercial demand for voclosporin in a timely fashion.
- Unknown impact and difficulties imposed by the COVID-19 pandemic on Aurinia’s business operations including nonclinical, clinical, regulatory and commercial activities.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q1 2021
-1.4%
Avg return
Earnings day
-0.3%
Avg return
5 days after
+4.6%
Avg return
30 days after
41%
18 / 44 earnings
Positive
+25.7%
Q2 2021
Best reaction
-32.3%
Q3 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q2 2025 | — | — | — | |
| Q1 2026 | -7.0% | -1.6% | -2.6% | |
| Q4 2025 | -3.1% | -1.9% | -1.1% | |
| Q3 2025 | -3.4% | +8.5% | +8.1% | |
| Q1 2025 | +1.8% | +2.4% | +1.1% | |
| Q4 2024 | -5.0% | +1.6% | +4.3% | |
| Q3 2024 | +10.6% | +11.4% | +18.8% | |
| Q2 2024 | -6.5% | -4.4% | +15.8% | |
| Q1 2024 | -1.9% | -1.5% | +4.2% | |
| Q4 2023 | -26.6% | -29.9% | -35.1% | |
| Q3 2023 | +15.4% | +16.3% | +27.1% | |
| Q2 2023 | -3.1% | -4.1% | -6.6% | |
| Q1 2023 | -1.1% | -4.2% | -18.4% | |
| Q4 2022 | +7.9% | +7.9% | +31.8% | |
| Q3 2022 | -32.3% | -29.3% | -33.0% | |
| Q2 2022 | -1.5% | -4.4% | -15.1% | |
| Q1 2022 | +7.1% | +24.9% | +35.2% | |
| Q4 2021 | -26.0% | -34.9% | -23.7% | |
| Q3 2021 | -0.3% | -2.1% | -41.7% | |
| Q2 2021 | +25.7% | +32.9% | +52.9% | |
| Q1 2021 | -17.3% | -8.5% | +1.7% | |
| Q4 2020 | +1.4% | +0.7% | -12.9% | |
| Q3 2020 | -4.0% | -3.1% | +7.3% | |
| Q2 2020 | -1.3% | -2.4% | -0.8% | |
| Q1 2020 | -2.3% | -3.7% | -11.7% | |
| Q4 2019 | -9.0% | -16.9% | -22.1% | |
| Q3 2019 | -2.4% | +13.6% | +245.4% | |
| Q2 2019 | -7.5% | -7.5% | -6.4% | |
| Q1 2019 | +4.3% | +8.9% | +3.6% | |
| Q4 2018 | +8.9% | +3.2% | +0.6% | |
| Q3 2018 | +1.3% | -6.5% | +9.7% | |
| Q2 2018 | +0.4% | -0.9% | +0.4% | |
| Q1 2018 | +7.3% | +20.3% | +5.7% | |
| Q4 2017 | +6.5% | +0.8% | +1.5% | |
| Q3 2017 | -11.0% | -8.5% | -15.3% | |
| Q2 2017 | +1.7% | +4.4% | +13.3% | |
| Q1 2017 | -4.6% | -6.6% | -22.3% | |
| Q4 2016 | +18.7% | -1.5% | -11.0% | |
| Q3 2016 | +1.2% | -0.8% | +13.3% | |
| Q2 2016 | +4.9% | +17.7% | -41.4% | |
| Q1 2016 | — | — | — | |
| Q4 2015 | +0.0% | — | — | |
| Q3 2015 | -4.8% | — | — | |
| Q2 2015 | -4.0% | — | — | |
| Q4 2014 | +4.9% | — | — | |
| Q3 2014 | -7.2% | — | — | |
| Q2 2014 | — | — | — | |
| Q1 2014 | — | — | — | |
| Q4 2013 | — | — | — | |
| Q3 2013 | — | — | — | |
| Q2 2013 | — | — | — | |
| Q1 2013 | — | — | — | |
| Q4 2012 | — | — | — | |
| Q3 2012 | — | — | — | |
| Q2 2012 | — | — | — | |
| Q1 2012 | — | — | — | |
| Q4 2011 | — | — | — | |
| Q3 2011 | — | — | — | |
| Q2 2011 | — | — | — | |
| Q1 2011 | — | — | — | |
| Q4 2010 | — | — | — | |
| Q3 2010 | — | — | — | |
| Q2 2010 | — | — | — | |
| Q1 2010 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro